company background image
GRPH logo

Graphite Bio NasdaqGM:GRPH Stock Report

Last Price

US$22.26

Market Cap

US$190.4m

7D

539.7%

1Y

861.6%

Updated

21 Mar, 2024

Data

Company Financials +

Graphite Bio, Inc.

NasdaqGM:GRPH Stock Report

Market Cap: US$190.4m

GRPH Stock Overview

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States.

GRPH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Graphite Bio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Graphite Bio
Historical stock prices
Current Share PriceUS$22.26
52 Week HighUS$22.62
52 Week LowUS$2.01
Beta0.20
1 Month Change654.58%
3 Month Change831.38%
1 Year Change861.56%
3 Year Changen/a
5 Year Changen/a
Change since IPO20.32%

Recent News & Updates

Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

Sep 20
Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

Recent updates

Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

Sep 20
Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

We're Hopeful That Graphite Bio (NASDAQ:GRPH) Will Use Its Cash Wisely

Jun 02
We're Hopeful That Graphite Bio (NASDAQ:GRPH) Will Use Its Cash Wisely

Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?

Feb 01
Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?

Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

Oct 05
Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

Graphite Bio doses first patient with GPH101 for sickle cell disease

Aug 11

Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?

Jun 22
Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?

Graphite Bio: Selling For Much Less Than Net Cash

May 25

Graphite Bio: An Important Stock To Track In The Gene Editing Space

Nov 18

Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans

Sep 25
Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans

Graphite Bio: Assessing Prospects Amid Doubts Raised On Safety Of Crispr

Aug 30

Shareholder Returns

GRPHUS BiotechsUS Market
7D539.7%0.9%0.2%
1Y861.6%11.0%28.1%

Return vs Industry: GRPH exceeded the US Biotechs industry which returned 12.6% over the past year.

Return vs Market: GRPH exceeded the US Market which returned 31.2% over the past year.

Price Volatility

Is GRPH's price volatile compared to industry and market?
GRPH volatility
GRPH Average Weekly Movement166.3%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: GRPH's share price has been volatile over the past 3 months.

Volatility Over Time: GRPH's weekly volatility has increased from 82% to 166% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20176Kim Drapkinhttps://graphitebio.com

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme.

Graphite Bio, Inc. Fundamentals Summary

How do Graphite Bio's earnings and revenue compare to its market cap?
GRPH fundamental statistics
Market capUS$190.43m
Earnings (TTM)-US$124.65m
Revenue (TTM)n/a

0.0x

P/S Ratio

-10.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GRPH income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$124.65m
Earnings-US$124.65m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.14
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GRPH perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.